Lamotrigine is a substrate for OCT1 in brain endothelial cells

Biochemical Pharmacology

Volumn 83, Issue 6, 2012, Pages 805-814

  Dickens, David ^a   Owen, Andrew ^a   Alfirevic, Ana ^a   Giannoudis, Athina ^a   Davies, Andrea ^a   Weksler, Babette ^b   Romero, Ignacio A ^c   Couraud, Pierre Olivier ^d,e,f   Pirmohamed, Munir ^a  

^a UNIVERSITY OF LIVERPOOL   (United Kingdom)

^b WEILL CORNELL MEDICAL COLLEGE   (United States)

^c OPEN UNIVERSITY   (United Kingdom)

^d INSTITUT COCHIN   (France)

^e CNRS   (France)

^f UNIVERSITÉ PARIS DESCARTES   (France)

Author keywords

Blood brain barrier; Drug drug interaction; hCMEC D3; Lamotrigine; OCT1; Quetiapine; SLC22A1

Indexed keywords

AMANTADINE; AURANTIIN; LAMOTRIGINE; MONTELUKAST; OCTAMER TRANSCRIPTION FACTOR 1; PRAZOSIN; PROBENECID; QUETIAPINE; VERAPAMIL;

ARTICLE; BLOOD BRAIN BARRIER; BRAIN CELL; CONCENTRATION (PARAMETERS); CONTROLLED STUDY; DISTRIBUTION VOLUME; DRUG TRANSPORT; DRUG UPTAKE; ENDOTHELIUM CELL; HUMAN; HUMAN CELL; HUMAN CELL CULTURE; IC 50; IN VITRO STUDY; LIPOPHILICITY; PH; PRIORITY JOURNAL; PROTEIN EXPRESSION;

ANTICONVULSANTS; BIOLOGICAL TRANSPORT; BLOOD-BRAIN BARRIER; BRAIN; CELL LINE; DIBENZOTHIAZEPINES; DRUG INTERACTIONS; ENDOTHELIAL CELLS; HUMANS; ORGANIC CATION TRANSPORTER 1; RNA, MESSENGER; TRIAZINES;

EID: 84857062912     PISSN: 00062952     EISSN: 18732968     Source Type: Journal    
DOI: 10.1016/j.bcp.2011.12.032     Document Type: Article

References (47)

1. M.C. Walker, X. Tong, H. Perry, M.S. Alavijeh, and P.N. Patsalos Comparison of serum, cerebrospinal fluid and brain extracellular fluid pharmacokinetics of lamotrigine Br J Pharmacol 130 2000 242 248 (Pubitemid 30261033)
2. N.Y. Walton, Q. Jaing, B. Hyun, and D.M. Treiman Lamotrigine vs. phenytoin for treatment of status epilepticus: comparison in an experimental model Epilepsy Res 24 1996 19 28 (Pubitemid 26191609)
3. M.M. Castel-Branco, A.C. Falcao, I.V. Figueiredo, M.M. Caramona, and J.M. Lanao Neuropharmacokinetic characterization of lamotrigine after its acute administration to rats Methods Find Exp Clin Pharmacol 27 2005 539 545 (Pubitemid 41727527)
4. S.G. Summerfield, K. Read, D.J. Begley, T. Obradovic, I.J. Hidalgo, and S. Coggon Central nervous system drug disposition: the relationship between in situ brain permeability and brain free fraction J Pharmacol Exp Ther 322 2007 205 213 (Pubitemid 46956363)
5. A. Fitton, and K.L. Goa Lamotrigine. An update of its pharmacology and therapeutic use in epilepsy Drugs 50 1995 691 713
6. T.A. Tran, I.E. Leppik, K. Blesi, S.T. Sathanandan, and R. Remmel Lamotrigine clearance during pregnancy Neurology 59 2002 251 255 (Pubitemid 34779186)
7. L.J. Hirsch, D. Weintraub, Y. Du, R. Buchsbaum, H.T. Spencer, and M. Hager Correlating lamotrigine serum concentrations with tolerability in patients with epilepsy Neurology 63 2004 1022 1026 (Pubitemid 39287910)
8. S. Jawad, A. Richens, G. Goodwin, and W.C. Yuen Controlled trial of lamotrigine (Lamictal) for refractory partial seizures Epilepsia 30 1989 356 363 (Pubitemid 19161399)
9. J.W. Sander, P.N. Patsalos, J.R. Oxley, M.J. Hamilton, and W.C. Yuen A randomised double-blind placebo-controlled add-on trial of lamotrigine in patients with severe epilepsy Epilepsy Res 6 1990 221 226 (Pubitemid 20255548)
10. C.D. Binnie, R.M. Debets, M. Engelsman, J.W. Meijer, H. Meinardi, and J. Overweg Double-blind crossover trial of lamotrigine (Lamictal) as add-on therapy in intractable epilepsy Epilepsy Res 4 1989 222 229 (Pubitemid 19271973)
11. N.J. Abbott, A.A. Patabendige, D.E. Dolman, S.R. Yusof, and D.J. Begley Structure and function of the blood-brain barrier Neurobiol Dis 37 2010 13 25
12. S. Ohtsuki, S. Hori, and T. Terasaki Molecular mechanisms of drug influx and efflux transport at the blood-brain barrier Nippon Yakurigaku Zasshi 122 2003 55 64 (Pubitemid 36834417)
13. B.B. Weksler, E.A. Subileau, N. Perriere, P. Charneau, K. Holloway, and M. Leveque Blood-brain barrier-specific properties of a human adult brain endothelial cell line FASEB J 19 2005 1872 1874 (Pubitemid 41598779)
14. H. Koepsell, K. Lips, and C. Volk Polyspecific organic cation transporters: structure, function, physiological roles, and biopharmaceutical implications Pharm Res 24 2007 1227 1251 (Pubitemid 46876495)
15. A. Davies, N.E. Jordanides, A. Giannoudis, C.M. Lucas, S. Hatziieremia, and R.J. Harris Nilotinib concentration in cell lines and primary CD34(+) chronic myeloid leukemia cells is not mediated by active uptake or efflux by major drug transporters Leukemia 23 2009 1999 2006
16. A. Giannoudis, A. Davies, C.M. Lucas, R.J. Harris, M. Pirmohamed, and R.E. Clark Effective dasatinib uptake may occur without human organic cation transporter 1 (hOCT1): implications for the treatment of imatinib-resistant chronic myeloid leukemia Blood 112 2008 3348 3354
17. M.W. Pfaffl A new mathematical model for relative quantification in real-time RT-PCR Nucleic Acids Res 29 2001 e45
18. P. Martin, R. Riley, D.J. Back, and A. Owen Comparison of the induction profile for drug disposition proteins by typical nuclear receptor activators in human hepatic and intestinal cells Br J Pharmacol 153 2008 805 819 (Pubitemid 351271752)
19. M.L. Andersson, L. Bjorkhem-Bergman, and J.D. Lindh Possible drug-drug interaction between quetiapine and lamotrigine - evidence from a Swedish TDM database Br J Clin Pharmacol 72 2011 153 156
20. A.G. Marson, A.M. Al-Kharusi, M. Alwaidh, R. Appleton, G.A. Baker, and D.W. Chadwick The SANAD study of effectiveness of carbamazepine, gabapentin, lamotrigine, oxcarbazepine, or topiramate for treatment of partial epilepsy: an unblinded randomised controlled trial Lancet 369 2007 1000 1015 (Pubitemid 46436124)
21. S.A. Hitchcock, and L.D. Pennington Structure-brain exposure relationships J Med Chem 49 2006 7559 7583 (Pubitemid 46033646)
22. F.P. Meyer, P. Banditt, A. Schubert, and J. Schoche Lamotrigine concentrations in human serum, brain tissue, and tumor tissue Epilepsia 40 1999 68 73 (Pubitemid 29031755)
23. J. Thomas, L. Wang, R.E. Clark, and M. Pirmohamed Active transport of imatinib into and out of cells: implications for drug resistance Blood 104 2004 3739 3745 (Pubitemid 39564452)
24. L. Wang, A. Giannoudis, S. Lane, P. Williamson, M. Pirmohamed, and R.E. Clark Expression of the uptake drug transporter hOCT1 is an important clinical determinant of the response to imatinib in chronic myeloid leukemia Clin Pharmacol Ther 83 2008 258 264
25. A.T. Nies, E. Herrmann, M. Brom, and D. Keppler Vectorial transport of the plant alkaloid berberine by double-transfected cells expressing the human organic cation transporter 1 (OCT1, SLC22A1) and the efflux pump MDR1 P-glycoprotein (ABCB1) Naunyn Schmiedebergs Arch Pharmacol 376 2008 449 461
26. A.T. Nies, U. Hofmann, C. Resch, E. Schaeffeler, M. Rius, and M. Schwab Proton pump inhibitors inhibit metformin uptake by organic cation transporters (OCTs) PLoS ONE 6 2011 e22163
27. M.V. Tzvetkov, S.V. Vormfelde, D. Balen, I. Meineke, T. Schmidt, and D. Sehrt The effects of genetic polymorphisms in the organic cation transporters OCT1, OCT2, and OCT3 on the renal clearance of metformin Clin Pharmacol Ther 86 2009 299 306
28. Y. Shu, C. Brown, R.A. Castro, R.J. Shi, E.T. Lin, and R.P. Owen Effect of genetic variation in the organic cation transporter 1, OCT1, on metformin pharmacokinetics Clin Pharmacol Ther 83 2008 273 280
29. C.J. Lin, Y. Tai, M.T. Huang, Y.F. Tsai, H.J. Hsu, and K.Y. Tzen Cellular localization of the organic cation transporters, OCT1 and OCT2, in brain microvessel endothelial cells and its implication for MPTP transport across the blood-brain barrier and MPTP-induced dopaminergic toxicity in rodents J Neurochem 114 2010 717 727
30. M.S. Khinchi, K.A. Nielsen, M. Dahl, and P. Wolf Lamotrigine therapeutic thresholds Seizure 17 2008 391 395
31. Y. Shu, M.K. Leabman, B. Feng, L.M. Mangravite, C.C. Huang, and D. Stryke Evolutionary conservation predicts function of variants of the human organic cation transporter, OCT1 Proc Natl Acad Sci USA 100 2003 5902 5907 (Pubitemid 36576905)
32. T. Sakata, N. Anzai, H.J. Shin, R. Noshiro, T. Hirata, and H. Yokoyama Novel single nucleotide polymorphisms of organic cation transporter 1 (SLC22A1) affecting transport functions Biochem Biophys Res Commun 313 2004 789 793 (Pubitemid 38021900)
33. A. Rowland, D.J. Elliot, J.A. Williams, P.I. Mackenzie, R.G. Dickinson, and J.O. Miners In vitro characterization of lamotrigine N2-glucuronidation and the lamotrigine-valproic acid interaction Drug Metab Dispos 34 2006 1055 1062 (Pubitemid 43763765)
34. A.W. Yuen, G. Land, B.C. Weatherley, and A.W. Peck Sodium valproate acutely inhibits lamotrigine metabolism Br J Clin Pharmacol 33 1992 511 513
35. P.N. Patsalos, and E. Perucca Clinically important drug interactions in epilepsy: interactions between antiepileptic drugs and other drugs Lancet Neurol 2 2003 473 481 (Pubitemid 36876104)
36. U. Ebert, N.Q. Thong, R. Oertel, and W. Kirch Effects of rifampicin and cimetidine on pharmacokinetics and pharmacodynamics of lamotrigine in healthy subjects Eur J Clin Pharmacol 56 2000 299 304 (Pubitemid 30462927)
37. G. Ahlin, J. Karlsson, J.M. Pedersen, L. Gustavsson, R. Larsson, and P. Matsson Structural requirements for drug inhibition of the liver specific human organic cation transport protein 1 J Med Chem 51 2008 5932 5942
38. C.L. DeVane, and C.B. Nemeroff Clinical pharmacokinetics of quetiapine: an atypical antipsychotic Clin Pharmacokinet 40 2001 509 522
39. Y.W. Wong, C. Yeh, and P.T. Thyrum The effects of concomitant phenytoin administration on the steady-state pharmacokinetics of quetiapine J Clin Psychopharmacol 21 2001 89 93 (Pubitemid 32096756)
40. G. Ahlin, L. Chen, L. Lazorova, Y. Chen, A.G. Ianculescu, and R.L. Davis Genotype-dependent effects of inhibitors of the organic cation transporter, OCT1: predictions of metformin interactions Pharmacogenomics J 23 2010 400 411
41. Y.M. Ahn, J.Y. Nam, J.L. Culver, W.K. Marsh, J.C. Bonner, and T.A. Ketter Lamotrigine plus quetiapine combination therapy in treatment-resistant bipolar depression Ann Clin Psychiatry 23 2011 17 24
42. D.M. Tishler, K.I. Weinberg, D.R. Hinton, N. Barbaro, G.M. Annett, and C. Raffel MDR1 gene expression in brain of patients with medically intractable epilepsy Epilepsia 36 1995 1 6
43. N. Akahoshi, Y.L. Murashima, T. Himi, Y. Ishizaki, and I. Ishii Increased expression of the lysosomal protease cathepsin S in hippocampal microglia following kainate-induced seizures Neurosci Lett 429 2007 136 141 (Pubitemid 350161122)
44. M.J. Dresser, M.K. Leabman, and K.M. Giacomini Transporters involved in the elimination of drugs in the kidney: organic anion transporters and organic cation transporters J Pharm Sci 90 2001 397 421 (Pubitemid 32298045)
45. M. Hayer-Zillgen, M. Bruss, and H. Bonisch Expression and pharmacological profile of the human organic cation transporters hOCT1, hOCT2 and hOCT3 Br J Pharmacol 136 2002 829 836 (Pubitemid 34836857)
46. G. Burckhardt, and N.A. Wolff Structure of renal organic anion and cation transporters Am J Physiol Renal Physiol 278 2000 F853 F866
47. T. Minematsu, M. Iwai, K. Sugimoto, N. Shirai, T. Nakahara, and T. Usui Carrier-mediated uptake of 1-(2-methoxyethyl)-2-methyl-4,9-dioxo-3-(pyrazin-2- ylmethyl)-4,9-dihydro-1H-naphtho[2,3-d]imidazolium bromide (YM155 monobromide), a novel small-molecule survivin suppressant, into human solid tumor and lymphoma cells Drug Metab Dispos 37 2009 619 628